The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $88.63

Today's change-1.38 -1.53%
Updated July 25 4:00 PM EDT. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $88.63

Today's change-1.38 -1.53%
Updated July 25 4:00 PM EDT. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc crosses below 20-day moving average

Biomarin Pharmaceutical Inc closed sharply lower Tuesday, dropping (U.S.)$1.38 or 1.53% to (U.S.)$88.63 and crossing below its 20-day moving average. Over the last five days, shares have gained 2.26% and 6.99% year to date. Shares have underperformed the S&P 500 by 18.72% during the last year.

Key company metrics

  • Open(U.S.) $90.50
  • Previous close(U.S.) $90.01
  • High(U.S.) $90.50
  • Low(U.S.) $88.33
  • Bid / Ask(U.S.) $87.61 / (U.S.) $89.50
  • YTD % change+6.99%
  • Volume1,004,926
  • Average volume (10-day)1,460,238
  • Average volume (1-month)1,413,815
  • Average volume (3-month)1,211,177
  • 52-week range(U.S.) $78.42 to (U.S.) $102.49
  • Beta1.84
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.41
Updated July 25 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-47.42%

Although this company's net profit margin is negative, it is above the industry average and implies that Biomarin Pharmaceutical Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.49%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue304300280300
Total other revenue--------
Total revenue304300280300
Gross profit254236229249
Total cost of revenue50645152
Total operating expense324390340873
Selling / general / administrative119153120110
Research & development145175161167
Depreciation / amortization8888
Interest expense (income), net operating--------
Unusual expense (income)--00599
Other operating expenses, total102-62
Operating income-20-90-60-573
Interest income (expense), net non-operating-10-10-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax-24-92-67-583
Income after tax-16-79-43-424
Income tax, total-8-13-24-159
Net income-16-79-43-424
Total adjustments to net income--------
Net income before extra. items-16-79-43-424
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-16-79-43-424
Inc. avail. to common incl. extra. items-16-79-43-424
Diluted net income-16-79-43-424
Dilution adjustment--------
Diluted weighted average shares173172168163
Diluted EPS excluding extraordinary itemsvalue per share-0.09-0.46-0.26-2.61
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.09-0.46-0.26-0.21